Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*-Reference-Cited by-同舟云学术

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*

Published:2020-09-06 Issue:1 Volume:184 Page:50-59
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Warren R.B.¹,Blauvelt A.²^ORCID,Poulin Y.³,Beeck S.⁴,Kelly M.⁴,Wu T.⁴,Geng Z.⁴,Paul C.⁵^ORCID

Affiliation:

1. The Dermatology Centre Salford Royal NHS Foundation TrustManchester NIHR Biomedical Research Centre Manchester UK

2. Oregon Medical Research Centre Portland OR USA

3. Laval University and Centre de Recherche Dermatologique du Québec Métropolitain Québec City QC Canada

4. AbbVie Inc. North Chicago IL USA

5. Paul Sabatier University and Larrey Hospital Toulouse France

Funder

AbbVie

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19341

Reference53 articles.

1. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

2. Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

3. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis

4. Psoriasis and comorbidities: links and risks;Ni C;Clin Cosmet Investig Dermatol,2014

5. Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

3. IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis;Journal of Clinical Medicine;2024-08-29

4. Association of partial infections with the risk of psoriasis: A two‐sample Mendelian randomization study;Skin Research and Technology;2024-08

5. Sequencing of Targeted Therapy in Psoriasis: Does it Matter?;American Journal of Clinical Dermatology;2024-07-13